Pulmonary pharmacology and therapeutics

Nintedanib for non-IPF progressive pulmonary fibrosis: 12-month outcome data from a real-world multicentre observational study
Lavanya Raman, Iain Stewart, Shaney L. Barratt, Felix Chua, Nazia Chaudhuri, Anjali Crawshaw, Michael Gibbons, Charlotte Hogben, Rachel Hoyles, Vasilis Kouranos, Jennifer Martinovic, Sarah Mulholland, Katherine J. Myall, Marium Naqvi, Elisabetta A. Renzoni, Peter Saunders, Matthew Steward, Dharmic Suresh, Muhunthan Thillai, Athol U. Wells, Alex West, Jane A. Mitchell, Peter M. George

ERJ Open Research Mar 2023, 9 (2) 00423-2022; DOI: 10.1183/23120541.00423-2022
AV-101, a novel inhaled dry-powder formulation of imatinib, in healthy adult participants: a phase 1 single and multiple ascending dose study
Hunter Gillies, Ralph Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam

ERJ Open Research Mar 2023, 9 (2) 00433-2022; DOI: 10.1183/23120541.00433-2022
Long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate-to-severe asthma: ATLAS trial design
Lucia De Prado Gomez, Ian Pavord, William Busse, Christopher E. Brightling, Michael E. Wechsler, Klaus F. Rabe, Mei Zhang, Jun Xing, Juby A. Jacob-Nara, Paul J. Rowe

ERJ Open Research Mar 2023, 9 (2) 00417-2022; DOI: 10.1183/23120541.00417-2022
Triple therapy in COPD: understanding the data
Samy Suissa

ERJ Open Research Jan 2023, 9 (1) 00615-2022; DOI: 10.1183/23120541.00615-2022
Use of inhaled ipratropium bromide to improve exercise-induced laryngeal obstruction cannot be recommended
Praveen Muralitharan, Petter Carlsen, Magnus Hilland, Irisz Delestre-Levai, Maria Vollsæter, Karl Ove Hufthammer, Mette Engan, Ola Drange Røksund, Thomas Halvorsen, Hege H. Clemm

ERJ Open Research Jan 2023, 9 (1) 00308-2022; DOI: 10.1183/23120541.00308-2022
Pharmacotherapy for lung cancer with comorbid interstitial pneumonia: limited evidence requires appropriate evaluation
Yuriko Ishida, Satoshi Ikeda, Akimasa Sekine, Tomohisa Baba, Takashi Ogura

ERJ Open Research Oct 2022, 8 (4) 00337-2022; DOI: 10.1183/23120541.00337-2022
Interferon-γ release assay screening in biologics: safe and reliable, but not perfect
John Cafferkey, Yorissa Padayachee, Sophia Kostich, Kartik Kumar, Paul Jewell, Mikin Patel, Aneeka Chavda, Alison Cox, Mirae Park, Georgina Russell, Meg Coleman, Laura Martin, Onn Min Kon

ERJ Open Research Oct 2022, 8 (4) 00193-2022; DOI: 10.1183/23120541.00193-2022
AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
Shahid Siddiqui, Claus Bachert, Adam M. Chaker, Joseph K. Han, Peter W. Hellings, Anju T. Peters, Enrico Heffler, Siddhesh Kamat, Haixin Zhang, Scott Nash, Asif H. Khan, Lucia De Prado Gomez, Juby A. Jacob-Nara, Paul J. Rowe, Yamo Deniz

ERJ Open Research Oct 2022, 8 (4) 00085-2022; DOI: 10.1183/23120541.00085-2022
Effect of nintedanib on acute exacerbations of fibrosing interstitial lung diseases: a national database study in Japan
Hirokazu Urushiyama, Taisuke Jo, Wakae Hasegawa, Akira Yokoyama, Takahiro Ando, Yukiyo Sakamoto, Ryosuke Kumazawa, Kazuaki Uda, Nobuaki Michihata, Nobuyasu Awano, Matsui Hiroki, Kiyohide Fushimi, Hideo Yasunaga, Takahide Nagase

ERJ Open Research Oct 2022, 8 (4) 00209-2022; DOI: 10.1183/23120541.00209-2022
Long-term effectiveness of dual CFTR modulator treatment of cystic fibrosis
Danya Muilwijk, Domenique D. Zomer-van Ommen, Vincent A.M. Gulmans, Marinus J.C. Eijkemans, Cornelis K. van der Ent, Dutch Cystic Fibrosis Registry (NCFR) Steering Group: , J. Altenburg, S.W.J. Terheggen-Lagro, H.G.M. Heijerman, K.M. de Winter-de Groot, M. Bakker, R.A.S. Hoek, H.M. Janssens, R. van der Meer, M. Nuijsink, H. van der Vaart, G.H. Koppelman, L.H. Conemans, M.A.G.E. Bannier, J.J. Noordhoek

ERJ Open Research Oct 2022, 8 (4) 00204-2022; DOI: 10.1183/23120541.00204-2022

Main menu

User menu

Search

Pulmonary pharmacology and therapeutics

Pages

Contact us